Dr. Yu Compares Treatment Options for Prostate Cancer

James B. Yu, MD
Published: Friday, Aug 04, 2017



James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

There is no survival difference between active surveillance and local therapy such as surgery and radiation, explains Yu. Quality of life data has recently been reported stating that there is better genitourinary and sexual function with 6 months of radiotherapy compared to surgery.

According to Yu, radiotherapy is the quality of life choice for patients versus surgery. More data will have to be reported to determine which treatment is ultimately the most beneficial for patient with prostate cancer.
 
SELECTED
LANGUAGE


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses radiotherapy versus surgery for patients with prostate cancer.

There is no survival difference between active surveillance and local therapy such as surgery and radiation, explains Yu. Quality of life data has recently been reported stating that there is better genitourinary and sexual function with 6 months of radiotherapy compared to surgery.

According to Yu, radiotherapy is the quality of life choice for patients versus surgery. More data will have to be reported to determine which treatment is ultimately the most beneficial for patient with prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x